Screener
Celldex Therapeutics CLDX EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091984
FAQ
- What is Celldex Therapeutics's EPS (basic)?
- Celldex Therapeutics (CLDX) reported EPS (basic) of -$0.94 in Q2 2026.
- How has Celldex Therapeutics's EPS (basic) changed year-over-year?
- Celldex Therapeutics's EPS (basic) decreased by 10.6% year-over-year, from -$0.85 to -$0.94.
- What is the long-term trend for Celldex Therapeutics's EPS (basic)?
- Over 4 years (2021 to 2025), Celldex Therapeutics's EPS (basic) has grown at a 24.2% compound annual growth rate (CAGR), from -$1.64 to -$3.90.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.
Ask your AI about Celldex Therapeutics's eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude